Analysis of the Efficacy and Safety of Dapagliflozin Combined with Standardized Drug Therapy in Patients with Refractory Heart Failure and Pacemaker Implantation
HAN Zhenhai
YAN Ni
HUI Lingling
Abstract：Objective To analyze the efficacy and safety of dapagliflozin combined with standardized drug therapy in patients with refractory heart failure and pacemaker implantation.Methods A retrospective study was conducted on 102 pa-tients with refractory heart failure and pacemaker implantation admitted to Xi'an Gaoxin Hospital in Shaanxi Province from May 2022 to May 2024.Patients were divided into a conventional group(standardized drug therapy,n=46)and a combination group(dapagliflozin added to standardized drug therapy,n=56).The clinical efficacy,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),and left ventricular posterior wall thickness(LVPWD)],inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and high-sensitivity C-reactive protein(hs-CRP)],and ad-verse reactions were compared between the two groups.Results The total effective rate was higher in the combination group than in the conventional group.After treatment,LVEF was higher,while LVEDD,LVPWD,TNF-α,IL-6,and hs-CRP were lower in the combination group,with statistically significant differences between the groups(all P<0.05).There was no signifi-cant difference in adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with standardized drug therapy has ideal efficacy in the treatment of refractory heart failure with pacemaker implantation,improving cardiac func-tion,regulating the expression of inflammatory factors,and demonstrating high safety.
Keywords：DapagliflozinStandardized drug therapyRefractory heart failurePacemaker implantation
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 2011-2014 )